| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | CT1.6; MAGE6; MAGE3B; MAGE-3b |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human MAGEA6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与SNRPN抗体相关的文献示例(注：文献信息为假设性示例，实际文献需通过数据库验证)：
1. **文献名称**: "SNRPN methylation analysis in Prader-Willi syndrome diagnosis"
**作者**: Driscoll DJ, et al.
**摘要**: 研究利用SNRPN抗体的甲基化特异性PCR技术，建立了Prader-Willi综合征的无创诊断方法，通过检测患者血液样本中SNRPN基因的甲基化状态，验证了该抗体在区分父系与母系等位基因中的高特异性。
2. **文献名称**: "Imprinting center regulation of SNRPN expression in neurons"
**作者**: Buiting K, et al.
**摘要**: 通过SNRPN抗体的免疫荧光和Western blot分析，揭示了印记控制区(IC)对神经元中SNRPN蛋白表达的调控机制，发现IC缺失导致SNRPN表达异常，可能与神经发育障碍相关。
3. **文献名称**: "Antibody-based detection of SNRPN in genomic imprinting disorders"
**作者**: Glenn CC, et al.
**摘要**: 开发了一种基于SNRPN抗体的ELISA检测法，用于快速筛查Angelman综合征和Prader-Willi综合征患者，验证了该抗体在区分印记缺陷类型中的临床应用潜力，敏感度达95%以上。
4. **文献名称**: "SNRPN antibody validation for epigenetic studies"
**作者**: Horsthemke B, et al.
**摘要**: 系统评估了SNRPN抗体在染色质免疫沉淀(ChIP)和蛋白质相互作用研究中的效能，证实其适用于探究SNRPN蛋白在印记基因簇复合体形成中的关键作用。
---
**注意**：以上文献信息为示例性质，实际引用需通过PubMed、Google Scholar等平台检索真实文献。SNRPN抗体相关研究多集中于基因组印记机制、神经发育疾病诊断及表观遗传学方法学领域。
SNRPN (Small Nuclear Ribonucleoprotein Polypeptide N) antibodies are autoantibodies targeting components of the spliceosome, a complex involved in RNA processing. The SNRPN gene, located on chromosome 15q11.2. is part of a critical imprinted region linked to Prader-Willi and Angelman syndromes. While SNRPN's primary role relates to mRNA splicing and neurodevelopmental regulation, autoantibodies against SNRPN are not directly tied to these syndromes but are instead associated with autoimmune conditions.
These antibodies are notably identified in a subset of patients with dermatomyositis (DM), particularly those presenting with cancer-associated myositis. Studies suggest SNRPN antibodies may serve as a serological marker for paraneoplastic DM, aiding in cancer screening for affected individuals. They are detected via immunoprecipitation or line immunoassays, often co-occurring with other myositis-specific autoantibodies.
The pathogenic role of SNRPN antibodies remains unclear, though their presence highlights dysregulated immune responses targeting spliceosomal components. Research continues to explore their clinical utility in disease stratification, prognosis prediction, and understanding molecular mechanisms linking autoimmunity and malignancy. Their discovery underscores the complexity of autoimmune responses and the spliceosome's immunogenicity in certain rheumatic diseases.
×
